Glycoprotein VI antibodies and methods thereof
The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and immunotherapeutic agents, in particular, as antithrombotic therapeutic agents.
1. A monoclonal antibody specific for a glycoprotein VI (GPVI) polypeptide or peptide, wherein the monoclonal antibody inhibits collagen-induced platelet aggregation at an IC 50 of less than 7 μg/ml, wherein the IC 50 is determined using a concentration of collagen that induces 70-90% platelet aggregation within 5 minutes of its contact with platelets in a platelet aggregation assay, wherein the monoclonal antibody specifically binds to a GPVI polypeptide or peptide at a Kd of lower than 10 −8 M, and wherein the monoclonal antibody is selected from OM1 (ATCC No. PTA-5938), OM2 (ATCC No. PTA-5939), OM3 (ATCC No. PTA-5940), and OM4 (ATCC No. PTA-5941).
2. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is OM1.
3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is OM2.
4. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is OM3.
5. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is OM4.
6. An antithrombotic composition comprising a pharmaceutically effective amount of at least one monoclonal antibody of claims 1 - 5 and a pharmaceutically acceptable excipient.
7. A method of making an antithrombotic composition comprising admixing at least one monoclonal antibody of claims 1 - 5 in a pharmaceutically acceptable excipient.
8. A kit comprising at least one dose of a pharmaceutically effective amount of at least one monoclonal antibody of claims 1 - 5 in a container.